-
Pfizer reports mixed results in late-stage clinical trial
NEW YORK Pfizer reported mixed results this week in a late-stage clinical trial combining two drugs in patients with advanced non-small cell lung cancer.
The drug maker said the combination of Pfizer’s Sutent (sunitinib) and Tarceva (erlotinib), made by Genentech and OSI Pharmaceuticals, kept the disease from progressing, but did not improve patients’ overall survival, which was the trial’s primary goal. The company expects to present results at the European Society for Medical Oncology Congress in Milan in October.